{"created":"2023-06-19T10:28:28.902815+00:00","id":619,"links":{},"metadata":{"_buckets":{"deposit":"8b20def7-801b-433f-95fb-c0e38a92fda9"},"_deposit":{"created_by":25,"id":"619","owners":[25],"pid":{"revision_id":0,"type":"depid","value":"619"},"status":"published"},"_oai":{"id":"oai:kwmed.repo.nii.ac.jp:00000619","sets":["1709617079800:35:186:431"]},"author_link":["120230","120231"],"item_1694495855422":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"VoR"}]},"item_3_biblio_info_12":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1987","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"278","bibliographicPageStart":"266","bibliographicVolumeNumber":"13","bibliographic_titles":[{"bibliographic_title":"川崎医学会誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Kawasaki medical journal","bibliographic_titleLang":"en"}]}]},"item_3_description_8":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_description":"原著","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_3_identifier_14":{"attribute_name":"URL","attribute_value_mlt":[{"subitem_identifier_type":"URI","subitem_identifier_uri":"http://igakkai.kms-igakkai.com/wp/wp-content/uploads/1987/KMJ13(3)266-278.1987.pdf"}]},"item_3_relation_20":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.11482/KMJ-J13(3)266 ","subitem_relation_type_select":"DOI"}}]},"item_3_source_id_1":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AN00045593","subitem_source_identifier_type":"NCID"},{"subitem_source_identifier":"AN12940574","subitem_source_identifier_type":"NCID"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0386-5924","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2758-089X","subitem_source_identifier_type":"EISSN"}]},"item_3_text_6":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学消化器外科"}]},"item_3_text_7":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Division of Gastroenterology, Department of Surgery, Kawasaki Medical School"}]},"item_3_textarea_10":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_textarea_language":"ja","subitem_textarea_value":"Ca2+拮抗剤Verapamilを制癌剤,主として5-FU(その他ADM,VCR,BLM)と併用し,その抗腫瘍効果に及ぼす影響を,まず培養細胞を用いin vitroで検索,ついでこの成績にもとづきin vivoの実験として,担癌マウスに5-FUとVerapamilを連日併用投与し,survivalに及ぼす影響をも検討した.I.In vitro(1)Verapamilは単独でも高濃度では増殖抑制がみられたが,5μM以下の低濃度ではほとんど影響しなかった.(2)増殖に影響のない濃度のVerapamilを5-FUと併用すると,制癌剤が低濃度であるほどより大きい効果増強が認められた.(3)14C-5-FUを用いた細胞内取り込み実験では,14C-5-FUは細胞内へ経時的に移行するが,これにVerapamil 5μMを併用すると,無添加の14C-5-FU単独群に比べて,5-FUの移行は有意に高値となった.II.In vivo(1)Verapamil単独では,大量を負荷しても抗腫瘍効果はみられなかった.(2)5-FU 5mg/kgとVerapamil 20mg/kgを併用すると,投与期間に関係なく併用効果を認め,5-FU単独群に比べ有意の生存期間の延長を得,低濃度で併用効果のあることが判った.(3)5-FUとVerapamil 40mg/kgとの併用は,併用にもとづく副作用が出現し,5-FU単独投与群に比べ生存期間はかえって短縮した.以上より,5-FUにおいてもVerapamilとの併用効果が示されたが,その機序についてはいまだ不明な点が多い.5-FUとVerapamilの併用は,投与方法や投与量の決定にはなお慎重を要すとしても,癌化学療法における効果増強の新しい可能性として期待される."}]},"item_3_textarea_11":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_textarea_language":"en","subitem_textarea_value":"The influence of the Ca2+ antagonist on anticancer agents has not as yet well been clarified. Many reports have implied that the Ca2+ antagonist enhances the effect of anticancer drugs (Vinca-alkaloid, anthracycline agents) on drug resistant cells. However, there have been a few reports on the effect of the Ca2+ antagonist on sensitive tumor cells. This report deals with the effect of Verapamil as at of the Ca2+ antagonist on chiefly 5-FU on Ehrlich ascites tumor cells (EA cells), both in vitro and in vivo. I. In vitro (1) Verapamil inhibited the growth of EA cells by itself at a high concentration. (2) Verapamil enhanced greatly the cytotoxicity of 5-FU at a noncytotoxic dose, and even at a low concentration. (3) A kinetic experiment showed that the uptake of 14C-5-FU into EA cells increased with time. It was observed that the amount of cellular 14C-5-FU is greatly increased in the presence of 5μM Verapamil. II. In vivo (1) Verapamil alone showed no therapeutic effect even at a high dose. (2) When 5-FU (5mg/kg) was administered with Verapamil (20mg/kg), the life span of EA cell-bearing mice was significantly prolongated, irrespective of administration. (3) When 5-FU was administered with Verapamil (40mg/kg), an inverse effect appeared, and the life span was shortened as compared with the group of mice to whom 5-FU was administered alone. These results suggest that the combined use of Verapamil with 5-FU may provide better treatment for human cancer, although the mechanism still remains unknown."}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"岩本, 末治","creatorNameLang":"ja"},{"creatorName":"イワモト, スエハル","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"120230","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Iwamoto, Sueharu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"120231","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-01-23"}],"displaytype":"detail","filename":"KJ00009816819.pdf","filesize":[{"value":"2.5 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KJ00009816819.pdf","objectType":"fulltext","url":"https://kwmed.repo.nii.ac.jp/record/619/files/KJ00009816819.pdf"},"version_id":"e3968389-b4aa-4436-8ab2-0926701d672f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Ca2+ antagonist","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Membrane transport","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cancer chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Ca2+拮抗剤併用癌化学療法の基礎的検討 : In vitro, In vivoにおける効果と解析","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Ca2+拮抗剤併用癌化学療法の基礎的検討 : In vitro, In vivoにおける効果と解析","subitem_title_language":"ja"},{"subitem_title":"Fundamental Studies on Cancer Chemotherapy Combined with Ca2+ Antagonist : In Vitro and In Vivo Studies","subitem_title_language":"en"}]},"item_type_id":"3","owner":"25","path":["431"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2017-01-23"},"publish_date":"2017-01-23","publish_status":"0","recid":"619","relation_version_is_last":true,"title":["Ca2+拮抗剤併用癌化学療法の基礎的検討 : In vitro, In vivoにおける効果と解析"],"weko_creator_id":"25","weko_shared_id":-1},"updated":"2023-10-06T04:23:09.173350+00:00"}